Financial Reporting - BeiGene, Ltd. filed its 2024 Annual Report with the STAR Market of the Shanghai Stock Exchange on April 28, 2025[5]. - The STAR Annual Report includes financial information for the year ended December 31, 2024, prepared in accordance with PRC GAAP[6]. - Financial information prepared under U.S. GAAP is also included, highlighting differences between PRC GAAP and U.S. GAAP[6]. - The financial information in the report is intended to be furnished and not deemed "filed" under the Exchange Act[8]. Key Financial Metrics - The report contains details on gross profit margin ratio and research and development expenses allocated by key products[6]. Public Availability - The STAR Annual Report is publicly available in Chinese on the Shanghai Stock Exchange's website[7]. Strategic Insights - The report does not include any new product launches or market expansion strategies[5][6]. - No specific performance guidance or future outlook was provided in the current report[5][6]. - The report does not mention any mergers or acquisitions during the reporting period[5][6]. Signatory Information - The filing was signed by Chan Lee, Senior Vice President and General Counsel of BeiGene, Ltd.[16].
BeiGene(BGNE) - 2025 Q1 - Quarterly Results